GH Research to present GH001 depression trial data at ECNP 2026 meeting

PUBT · 1d ago
GH Research to present GH001 depression trial data at ECNP 2026 meeting
  • GH Research plc set three posters for ECNP 2026 featuring data from its GH001-TRD-201 and GH001-BD-202 depression trials.
  • Results have not yet been presented; disclosures are scheduled for Poster Session 2 on Oct. 11, 2026, in Munich.
  • Planned presentations focus on clinical findings from studies in treatment-resistant depression and bipolar depression, without reporting outcomes in the announcement.
  • An ECNP industry satellite symposium on rapid-acting antidepressants is scheduled for Oct. 10, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-039191), on October 09, 2026, and is solely responsible for the information contained therein.